Core Viewpoint - Biophytis is positioning itself as a leader in addressing the muscle mass loss associated with GLP-1 therapies for obesity, focusing on the quality of weight loss and mobility restoration for patients [1][4]. Group 1: Company Overview - Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its lead drug candidate BIO101 targeting muscular diseases and metabolic disorders [5]. - The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, and Brazil, and its shares are listed on Euronext Growth Paris and the OTC market [5]. Group 2: Product Development - The drug candidate BIO101, when combined with GLP-1 therapies, has shown preclinical results indicating it enables high-quality weight loss while improving muscle function and strength [2]. - Biophytis is specifically targeting patients with obesity who are treated with GLP-1 therapies, addressing a significant unmet medical need [2][3]. Group 3: Market Potential - The global obesity market is projected to reach $100 billion by 2030, highlighting the substantial market opportunity for Biophytis [3]. - A significant 96% of patients with obesity experience impairment in muscle strength, underscoring the need for solutions that preserve muscle mass during weight loss [3]. Group 4: Competitive Landscape - Biophytis is the only company focusing on muscle quality and mobility restoration in the context of obesity treatment, differentiating itself from competitors [3]. - The acquisition of Versanis by Lilly for nearly $2 billion in 2023 indicates a growing recognition in the pharmaceutical industry of the need to combine GLP-1s with other treatments to mitigate muscle mass loss [3].

Group 1 - Biophytis has confirmed the launch of the Phase 2 OBA clinical trial in obesity, expected to begin as early as possible in 2025 [1] - The company recently announced a €2.6 million capital increase and will continue the clinical development of BIO101 in obesity, aiming to evaluate its efficacy and safety in reducing muscle strength loss caused by GLP-1 agonists in patients with obesity [2] - Biophytis received Investigational New Drug (IND) clearance from the FDA in July 2024, marking a significant milestone for the OBA program [3] Group 2 - The CEO of Biophytis stated that the company's priority is to find a pharmaceutical partner to co-develop BIO101 in obesity, which will support clinical and regulatory development through to marketing authorization [4] - Biophytis SA is focused on developing drug candidates for age-related diseases, with BIO101 being its lead drug candidate targeting muscular diseases, respiratory diseases, and metabolic disorders [4]

Core Insights - Biophytis SA announces new preclinical data supporting its investigational drug BIO101 aimed at restoring mobility in patients with obesity [1][5] - The combination of BIO101 with GLP-1 receptor agonists shows significant improvements in muscle strength and mobility in preclinical studies [2][7] Company Overview - Biophytis is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its lead drug candidate BIO101 targeting muscular diseases and metabolic disorders [6] Research Findings - The preclinical study demonstrated that the combination treatment of BIO101 and GLP-1 significantly improved mobility and grip strength in diet-induced obese mice compared to untreated groups [2][3] - Previous early-phase clinical trials indicated that BIO101 improved muscle strength and mobility in obese patient cohorts compared to placebo [3] Health Context - Obesity is a global health crisis affecting nearly one billion people, with 96% of patients reporting a decline in muscle strength, which impacts mobility [4][7] - The CEO of Biophytis emphasized the need for therapies that restore muscle strength and mobility in obesity patients, highlighting the company's commitment to addressing this unmet medical need [5]

Group 1 - Biophytis SA has published the Phase 2 clinical trial results for its lead drug candidate BIO101 in the Journal of Cachexia, Sarcopenia and Muscle, marking a significant milestone in the treatment of sarcopenia [1][3] - The company is progressing towards regulatory approvals for its Phase 3 trial in sarcopenia and is in discussions with a major international pharmaceutical company in China and other partners in Asia [2] - Sarcopenia currently affects between 121 and 194 million people globally, with no existing therapeutic solutions, positioning Biophytis as a leader in this indication with BIO101 [5] Group 2 - BIO101, at a dosage of 350mg bid, has shown a clinically meaningful improvement in the 400-meter walk test, which is the primary endpoint of the study [4] - The safety profile of BIO101 is excellent, with no serious adverse events related to the product reported at any dosage [4] - The treatment effect of BIO101 is notably significant in high-risk populations, particularly among slow walkers and those with sarcopenic obesity [4]

Core Points - Biophytis SA is participating in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) from March 12 to 14 in Toulouse, focusing on age-related diseases [1][2] - The ICFSR is a significant annual event aimed at advancing clinical trials for frail older adults, featuring rigorous peer-reviewed research published in the Journal of Frailty and Aging [2] - Biophytis will present preliminary data on its lead drug candidate BIO101, which targets muscle preservation in obese patients treated with GLP-1 receptor agonists [3] Company Overview - Biophytis SA is a clinical-stage biotechnology company developing drug candidates for age-related diseases, with its lead candidate BIO101 in Phase 3 for sarcopenia and Phase 1-2 for Duchenne muscular dystrophy [3] - The company also has completed Phase 2-3 trials for COVID-19 and is preparing to start Phase 2 trials for obesity [3] - Biophytis is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, and Brazil, and its shares are listed on Euronext Growth Paris and OTC market [3]

Core Insights - Biophytis has outlined its strategic outlook for 2025, focusing on accelerating the clinical development and commercialization of its lead drug candidate, BIO101 (20-Hydroxyecdysone) [1][2] - The company aims to enhance its competitive positioning through partnerships and collaborations across the Americas, Europe, and Asia, particularly targeting obesity and sarcopenia indications [2][5] Group 1: Clinical Development Initiatives - Biophytis will initiate the Phase 2 OBA study for BIO101 in obesity, collaborating with Blanver and other potential partners, to evaluate efficacy in obese patients [3][4] - The obesity market is projected to reach $100 billion by 2030, indicating a significant opportunity for Biophytis [3] - The company plans to launch Phase 3 of its SARA clinical program to confirm the efficacy of BIO101 in sarcopenia, addressing a public health issue affecting approximately 30 million patients in China [4] Group 2: Strategic Partnerships and Agreements - Biophytis has signed a strategic licensing agreement with Blanver and is in exclusive negotiations with a major Chinese pharmaceutical company [7] - The company has also concluded a co-development agreement with AskHelpU for ALS, further strengthening its collaborative efforts [7] Group 3: Financial and Operational Positioning - The company has improved its competitive fundamentals, which will support the execution of its strategic roadmap for 2025 [2] - Biophytis is committed to addressing crucial public health issues while consolidating its growth and impact across key geographies [5]

Group 1 - Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its lead drug candidate BIO101 targeting muscular diseases, respiratory diseases, and metabolic disorders [3] - The company will participate in the Biomed Forum on February 4, 2025, in Paris, which is an annual event aimed at connecting biotech and medtech companies with institutional investors [2] - The participation in the forum will provide Biophytis an opportunity to engage with French and European investors and share updates on its latest developments and outlook for 2025 [2] Group 2 - Biophytis is headquartered in Paris, France, and has subsidiaries in Cambridge, Massachusetts, USA, and Brazil, with its ordinary shares listed on Euronext Growth Paris and American Depositary Shares on the OTC market [3]

Core Viewpoint - Biophytis has signed a co-development agreement with AskHelpU to evaluate the efficacy of its lead drug candidate BIO101 for treating Amyotrophic Lateral Sclerosis (ALS) in China [1][2][3] Company Overview - Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its lead drug candidate BIO101 targeting muscular diseases, respiratory diseases, and metabolic disorders [5] - The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil, and its shares are listed on Euronext Growth Paris [5] Partnership Details - The agreement with AskHelpU aims to leverage Biophytis' expertise in drug development and AskHelpU's knowledge of ALS, utilizing top Chinese universities and research laboratories for experiments [3] - AskHelpU, founded by Cai Lei, is the largest ALS patient association in China, connecting over 15,000 individuals affected by neurodegenerative diseases [6] Market Context - ALS has a global prevalence of 4.1 to 8.4 patients per 100,000 inhabitants, with approximately 200,000 patients in China, representing a significant market for new treatment development [4] - The partnership signifies a unique opportunity for Biophytis to expand the potential applications of BIO101, which is also in development for other conditions such as sarcopenia and obesity [2][3]

Biophytis S.A.’s (BPTS) shares surged 63.1% in the after-market hours on Apr 8, after the company announced the launch of a phase II study called OBA, with its pipeline candidate, BIO101 (20-hydroxyecdysone), to treat obesity in combination with GLP-1 receptor agonists (GLP-1 RA).Biophytis’ BIO101 is the first oral daily MAS receptor activator that is expected to prevent extensive muscle loss due to obesity treatment. Currently, approved GLP-1 RA drugs for obesity, indicated in conjunction with dieting, are ...

Biophytis (NASDAQ:BPTS) stock is rocketing higher on Tuesday after releasing its earnings results for the full year of 2023.Biophytis  is still a clinical-stage biotechnology, which means it had no revenue to report for 2023. However, its net loss for the quarter was 17.03 million euros. That’s an improvement over its net loss of 24.22 million euros in 2022.Biophytis notes there were several factors that resulted in it reporting a lower net loss. That includes reduced research and development costs due to c ...